Reported about 1 year ago
Eli Lilly, a leading healthcare company, is valued at over $800 billion and has excelled in various medical fields with products like Kisunla for Alzheimer’s and Zepbound and Mounjaro for obesity. Its financials show a 26% increase in total revenue and a 67% rise in net income compared to the previous year. Big Money investors are optimistic about the company's future, given its strong fundamentals and institutional support. Eli Lilly's shares have surged by 54% this year, reflecting extraordinary demand and potential for further growth.
Source: YAHOO